Capture of an early fusion-active conformation of HIV-1 gp41.
Using an inhibitory synthetic peptide (DP-178) from HIV-1 gp41, we have trapped HIV-1 envelope glycoprotein (Env) undergoing conformational changes during virus entry. Our data show that DP-178 binds gp41 and inhibits Env-mediated membrane fusion after gp120 interacts with cellular receptors, indicating that conformational changes involving the coiled coil domain of gp41 are required for entry. Capture of this fusion-active conformation of Env provides insights into the early events leading to Env-mediated membrane fusion.
Furuta
R A
RA
Office of Vaccines, Center for Biologics Evaluation and Research, Food and Drug Administration, Bethesda, Maryland 20892-4555, USA.
Wild
C T
CT
Weng
Y
Y
Weiss
C D
CD
D016475:3T3 Cells; D000595:Amino Acid Sequence; D000818:Animals; D019380:Anti-HIV Agents / Q000494:pharmacology; D002459:Cell Fusion / Q000187:drug effects; D002460:Cell Line; D000077560:Enfuvirtide; D015700:HIV Envelope Protein gp41 / Q000737:chemistry* / Q000378:metabolism* / Q000494:pharmacology; D015497:HIV-1 / Q000187:drug effects / Q000502:physiology*; D006801:Humans; D008561:Membrane Fusion / Q000187:drug effects / Q000502:physiology*; D051379:Mice; D008954:Models, Biological; D008958:Models, Molecular; D008969:Molecular Sequence Data; D010446:Peptide Fragments / Q000494:pharmacology; D011487:Protein Conformation; D019707:Receptors, Chemokine / Q000187:drug effects / Q000502:physiology; D015728:Receptors, HIV / Q000187:drug effects / Q000502:physiology; D011993:Recombinant Fusion Proteins / Q000737:chemistry / Q000378:metabolism; D014162:Transfection
D019380:Anti-HIV Agents; D015700:HIV Envelope Protein gp41; D010446:Peptide Fragments; D019707:Receptors, Chemokine; D015728:Receptors, HIV; D011993:Recombinant Fusion Proteins; D000077560:Enfuvirtide